Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|May 17, 2023
EMA Issues Drug Safety Reminders
Author(s)Susan Haigney
The agency’s safety committee is reviewing hydroxyprogesterone medicines and issuing a reminder on safety issues regarding fluoroquinolone antibiotics.
Advertisement
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) met on May 10–12, 2023 to review medicines containing hydroxyprogesterone due to safety and effectiveness concerns. Hydroxyprogesterone caproate is available in the European Union and is given by injection to prevent pregnancy loss or premature birth. These medicines are also given in some countries to treat various gynecological disorders, according to the agency.
The French medicines agency requested PRAC review the medicines after a study suggested patients exposed to the drugs may have an increased risk of cancer that would increase when the drug was used in the first trimester of pregnancy and with the number of injections.
PRAC also issued a reminder about the risks associated with the use of fluoroquinolone antibiotics and said they should not be used to treat infections that might get better without treatment or to treat non-bacterial infections or mild bacterial infections. The restrictions imposed on these medicines were a result of a study that showed the risk of disabling, long-lasting side effects.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement